IGF-I and IGF-II in relation to colorectal cancer

Abstract

Recent data suggest that the IGF system plays an important role in the pathogenesis of several forms of human cancer, and there is evidence that IGFs acting in an autocrine and paracrine manner may also affect colorectal cancer risk. We have conducted a case‐control study on the island of Crete, Greece, to examine the potential relation between circulating IGF‐I and ‐II and their major binding protein (IGF‐BP3), on the one hand, and colorectal cancer, on the other. IGF‐I, IGF‐II and IGF‐BP3 were determined in the serum from 41 patients with colorectal cancer and 50 healthy controls; data were analyzed using unconditional multiple logistic regression, adjusting for age, gender, education, height and BMI, as well as mutually. Both IGF‐I and IGF‐II were positively, while IGF‐BP3 was inversely, associated with risk for colorectal cancer, though none of these relations reached statistical significance. However, individuals with IGF‐I and –II values in the upper 2 tertiles of the respective distributions had a significantly elevated odds ratio for colorectal cancer (OR = 5.2, 95% confidence interval 1.0–26.8) compared with those in the lower tertile in both distributions. Our results provide evidence that high levels of circulating IGF‐I and ‐II might be associated with colorectal cancer. Int. J. Cancer 83:15–17, 1999. © 1999 Wiley‐Liss, Inc.

Serum Insulin‐like Growth Factors, Insulin‐like Growth Factor‐binding Protein‐3, and Risk of Lung Cancer Death: A Case‐control Study Nested in the Japan Collaborative Cohort (JACC) Study

“…The two molecules, however, were not independently related to the risk when mutually adjusted. As in other studies, 9,25,26) IGF-II had a strong positive correlation with IGFBP-3. Therefore, it may be difficult to determine the independent effects of the two peptides even by using multivariate models.…”

Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines

“…Bogazzi et al recently reported on yearly colonoscopic screening over a 5-year period and observed IGF1 levels to be higher in individuals who developed multiple new adenomas (30). This influence of IGF1 in the development of colonic neoplasia is in keeping with its known proliferative and anti-apoptotic effects, and increased proliferation of the colonic epithelium in proportion to IGF1 levels has been recorded in acromegalic individuals (31). Furthermore, in the non-acromegalic population, individuals with higher IGF1 levels have an increased risk of developing colonic cancer (32,33).…”

Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma

“…The expression of IGF-IR mRNA (data not shown) and IGF-IR and pIGF-IR proteins was also detected in serumdeprived MCL cell lines, suggesting that the expression and activation of IGF-IR are not necessarily dependent on the presence of IGF-I in the surrounding microenvironment. However, it has been shown that circulating IGF-I is increased in cancer patients, [40][41] and it is still possible that the release of IGF-I from surrounding lymph node stromal cells or from remote sources such as liver parenchyma could induce further enhancement of IGF-IR signaling in MCL. It is of note that circulating IGF-I levels are not known in patients with lymphoma, including those with MCL, and it will be of great interest to systematically explore these levels in future studies.…”